A pending rule that would have established a new pathway to accelerate coverage of novel medical devices was withdrawn from consideration by the US Centers for Medicare and Medicaid Services, as well as the Office of Management and Budget's Office of Information and Regulatory Affairs (OIRA), in early January. But the move should not be interpreted as a sign that the Medicare agency has given up on strategies to support faster Medicare reimbursements for soon-to-be approved medical technology, CMS says.
The "Expedited Coverage of Innovative Technology" (ExCITe) proposed rule was under consideration by OIRA for 10 months, including interactions between government officials and the device industry, before it was pulled.